Prodrug-activating systems in suicide gene therapy.

CJ Springer; I Niculescu-Duvaz

doi:10.1172/jci10001

Prodrug-activating systems in suicide gene therapy.

CJ Springer, I Niculescu-Duvaz

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer chemotherapy encompasses a large number of well-documented and clinically established methods for the treatment of malignant diseases. However, the efficacy of these approaches is often hampered by an insufficient therapeutic index, lack of specificity, and the emergence of drug-resistant cell subpopulations. One approach aimed at enhancing the selectivity of cancer chemotherapy for solid tumors relies on the application of gene therapy technologies.

Original language	English
Pages (from-to)	1161-1167
Number of pages	7
Journal	The Journal of clinical investigation
Volume	105
Issue number	9
DOIs	https://doi.org/10.1172/jci10001
Publication status	Published - May 2000

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1172/jci10001

Cite this

@article{0bea9774e3394e4e8e0fb1d8a4b3cd3d,

title = "Prodrug-activating systems in suicide gene therapy.",

abstract = "Cancer chemotherapy encompasses a large number of well-documented and clinically established methods for the treatment of malignant diseases. However, the efficacy of these approaches is often hampered by an insufficient therapeutic index, lack of specificity, and the emergence of drug-resistant cell subpopulations. One approach aimed at enhancing the selectivity of cancer chemotherapy for solid tumors relies on the application of gene therapy technologies.",

author = "CJ Springer and I Niculescu-Duvaz",

year = "2000",

month = may,

doi = "10.1172/jci10001",

language = "English",

volume = "105",

pages = "1161--1167",

journal = "The Journal of clinical investigation",

issn = "1558-8238",

publisher = "American Society for Clinical Investigation",

number = "9",

}

TY - JOUR

T1 - Prodrug-activating systems in suicide gene therapy.

AU - Springer, CJ

AU - Niculescu-Duvaz, I

PY - 2000/5

Y1 - 2000/5

N2 - Cancer chemotherapy encompasses a large number of well-documented and clinically established methods for the treatment of malignant diseases. However, the efficacy of these approaches is often hampered by an insufficient therapeutic index, lack of specificity, and the emergence of drug-resistant cell subpopulations. One approach aimed at enhancing the selectivity of cancer chemotherapy for solid tumors relies on the application of gene therapy technologies.

AB - Cancer chemotherapy encompasses a large number of well-documented and clinically established methods for the treatment of malignant diseases. However, the efficacy of these approaches is often hampered by an insufficient therapeutic index, lack of specificity, and the emergence of drug-resistant cell subpopulations. One approach aimed at enhancing the selectivity of cancer chemotherapy for solid tumors relies on the application of gene therapy technologies.

UR - http://europepmc.org/abstract/med/10791987

U2 - 10.1172/jci10001

DO - 10.1172/jci10001

M3 - Article

C2 - 10791987

VL - 105

SP - 1161

EP - 1167

JO - The Journal of clinical investigation

JF - The Journal of clinical investigation

SN - 1558-8238

IS - 9

ER -

Prodrug-activating systems in suicide gene therapy.

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this